People | May 11, 2026
Symeres appoints Henning Steinhagen as CEO to drive next phase of global growth
Steinhagen brings more than 25 years of leadership experience spanning pharma, biotech and the CRO/CDMO sector
Steinhagen brings more than 25 years of leadership experience spanning pharma, biotech and the CRO/CDMO sector
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
Capital infusion to accelerate Earendil’s R&D platform
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
Subscribe To Our Newsletter & Stay Updated
